January 21, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
| Re: | Adaptive Biotechnologies Corporation |
Registration Statement on Form S-1
File No. 333-235989
Acceleration Request
Requested Date: January 23, 2020
Requested Time: 4:30 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Adaptive Biotechnologies Corporation hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement to 4:30 p.m., Eastern Time, on January 23, 2020, or as soon thereafter as practicable.
Please confirm once the Registration Statement has been declared effective by calling Andrew Ledbetter of DLA Piper LLP (US) at (206) 839-4845. Please also contact him should you have any questions.
Very truly yours,
Adaptive Biotechnologies Corporation
| /s/ Chad Robins | ||
| Chad Robins | ||
| Chief Executive Officer | ||
| cc: | Chad Cohen, Chief Financial Officer |
Stacy Taylor, General Counsel
Adaptive Biotechnologies Corporation
Andrew Ledbetter, Esq.
Tyler Hollenbeck, Esq.
DLA Piper LLP (US)
James Evans, Esq.
Amanda Rose, Esq.
Jennifer Hitchcock, Esq.
Fenwick & West LLP